DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo


company name or ticker

Orexigen: It'll All Blow Over, Buy On Dips

Orexigen's Contrave Blunder Due To Weak Intellectual Property Position

Could This Surprising Drug Stop Heart Attacks Before They Happen?

Patients in a trial studying Orexigen's weight-loss drug Contrave suffered fewer heart attacks while taking the drug.

Vivus (VVUS) Highlighted As Weak On High Volume

Orexigen Soars: Good News Is Heart Data, Bad News Is Data May Be Compromised

Cardiovascular Safety Surprise: Wait, Then Buy Orexigen

Why Orexigen Therapeutics, Inc. Stock Exploded Higher

Orexigen Therapeutics looks like it has the first game-changing obesity drug on its hands. Here's what you need to know.

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

Vivus - Flat Qsymia Scripts Point To Needed Shift

Vivus Sinking With Dwindling Qsymia Market Share

See More Articles...